Jasper Van der Aart
Overview
Explore the profile of Jasper Van der Aart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McAteer M, McGowan D, Cook G, Leung H, Ng T, OConnor J, et al.
BMC Med
. 2025 Jan;
23(1):37.
PMID: 39849494
Background: The clinical translation of positron emission tomography (PET) radiotracers for cancer management presents complex challenges. We have developed consensus-based recommendations for preclinical and clinical assessment of novel and established...
2.
Hobor S, Al Bakir M, Hiley C, Skrzypski M, Frankell A, Bakker B, et al.
Nat Commun
. 2024 Jun;
15(1):4871.
PMID: 38871738
The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses remains unclear. Here,...
3.
Murphy P, Galette P, Van der Aart J, Janiczek R, Patel N, Brown A
Br J Radiol
. 2023 Jul;
96(1150):20211126.
PMID: 37393537
In 2008, the role of clinical imaging in oncology drug development was reviewed. The review outlined where imaging was being applied and considered the diverse demands across the phases of...
4.
Ekman S, Cselenyi Z, Varrone A, Jucaite A, Martin H, Schou M, et al.
Clin Transl Sci
. 2023 Feb;
16(6):955-965.
PMID: 36808835
Brain metastases (BMs) are associated with poor prognosis in epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). Osimertinib is a third-generation, irreversible, EGFR-tyrosine kinase inhibitor that potently...
5.
Bakker C, Van der Aart J, Labots G, Liptrot J, Cross D, Klaassen E, et al.
Drugs R D
. 2021 Jun;
21(3):295-304.
PMID: 34164794
Introduction: HTL0018318 is a selective muscarinic M receptor partial agonist under development for the symptomatic treatment of dementias, including Alzheimer's disease. Clinically, HTL0018318 would likely be used alone or in...
6.
Bakker C, Van der Aart J, Hart E, Klaassen E, Bergmann K, van Esdonk M, et al.
Alzheimers Dement (N Y)
. 2020 Oct;
6(1):e12093.
PMID: 33083515
Introduction: Gln-1062 (MEMOGAIN) is an intranasally administered lipophilic prodrug of galantamine. Based on high brain-to-blood concentrations observed in pre-clinical studies, Gln-1062 is expected to have superior cognitive efficacy compared to...
7.
Recourt K, Van der Aart J, Jacobs G, de Kam M, Drevets W, van Nueten L, et al.
J Psychopharmacol
. 2020 Apr;
34(9):1030-1042.
PMID: 32248747
Background: This is the first report of the pharmacodynamic (PD) effects of the selective, potent and brain-penetrant P2X7 receptor (P2X7R) antagonist JNJ-54175446. Activation of the P2X7R, an adenosine triphosphate-gated ion...
8.
Van der Aart J, Yaqub M, Kooijman E, Bakker J, Langermans J, Schuit R, et al.
Mol Imaging Biol
. 2018 Oct;
21(4):676-685.
PMID: 30306318
Purpose: There are currently no positron emission tomography (PET) radiotracers for the GluN2B (NR2B) binding sites of brain N-methyl-D-aspartate (NMDA) receptors. In rats, the GluN2B antagonist Ro25-6981 reduced the binding...
9.
Van der Aart J, Golla S, van der Pluijm M, Schwarte L, Schuit R, Klein P, et al.
EJNMMI Res
. 2018 Jul;
8(1):69.
PMID: 30054846
Background: Efforts to develop suitable positron emission tomography (PET) tracers for the ion channel site of human N-methyl-D-aspartate (NMDA) receptors have had limited success. [F]PK-209 is a GMOM derivative that...
10.
Van der Aart J, Salinas C, Dimber R, Pampols-Maso S, Weekes A, Tonkyn J, et al.
J Cereb Blood Flow Metab
. 2017 Jul;
38(11):2033-2040.
PMID: 28737056
We characterized the relationship between the plasma concentration of the phospodiesterase (PDE)-4 inhibitor GSK356278 and occupancy of the PDE4 enzyme in the brain of healthy volunteers, using the positron emission...